Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis
Cerebrovascular Diseases · 2023 · 52 (3) · 255-265
DOI: 10.1159/000526896 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cerebrovascular Diseases, online erschienen am 12.10.2022. Verfasst von Masaomi Koyanagi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
We investigated whether apixaban is safe for the prevention of further adverse events in non-valvular atrial fibrillation (NVAF) patients with intra-/extracranial artery stenosis (Stenosis group) compared with acute large vessel occlusion without intra-/extracranial artery stenosis (No stenosis group). We also examined whether combination therapy using apixaban and antiplatelet is safe.
Methods
ALVO (Apixaban on clinical outcome of patients with Large Vessel Occlusion [LVO] or stenosis) was a historical and prospective multicenter registry at 38 centers in Japan. Patients with NVAF and acute LVO or stenosis who received apixaban within 14 days after onset were included. We conducted the post hoc analysis using the ALVO dataset. We compared patients with stenosis versus those without stenosis in terms of the primary outcome, which was defined as a composite of all-cause death, major bleeding events, and ischemic events 365 days after onset.
Results
Of the 662 patients, 54 (8.2%) patients were classified into the Stenosis group, and 104 patients of the total (16%) reached the primary outcome. The cumulative incidence of primary outcome was not significantly different between the No stenosis and the Stenosis groups (hazard ratio [HR] 1.2, 95% confidence interval [CI]: 0.64–2.4; p = 0.52). Even after adjustment for predictive clinical variates, no significant difference in the primary endpoint between the No stenosis and the Stenosis groups was shown (adjusted HR 1.2, 95% CI: 0.59–2.5; p = 0.60). Fifty patients (7.6%) used an antiplatelet with apixaban. Among the Stenosis group patients, the cumulative incidence of the primary outcome was significantly higher among patients treated with an antiplatelet and apixaban (HR 3.5, 95% CI: 1.0–12; p = 0.048).
Conclusion
Apixaban monotherapy appears safe for the prevention of further adverse events in the Stenosis group patients similar to the No stenosis group patients. Concomitant use of an antiplatelet might not be favorable in patients with stenosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan.
- Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan.
- Department of Stroke Neurology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
- Department of Neurology, Tenri Yorozu Hospital, Nara, Japan.
- Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan.
- Department of Neurosurgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Zitieren
APA
Koyanagi, M., Hatano, T., Uchida, K., Ogura, T., Yamagami, H., Shibata, M., Enomoto, Y., Fukawa, N., Matsumoto, Y., Sakai, N., Takeuchi, M., Nonaka, T., Shimizu, F., Ezura, M., Ota, T., Ohta, H., Morimoto, M., Morimoto, T., Yoshimura, S., & ALVO investigators (2023). Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis. Cerebrovascular Diseases, 52(3), 255-265. https://doi.org/10.1159/000526896
Vancouver
Koyanagi M, Hatano T, Uchida K, Ogura T, Yamagami H, Shibata M, et al. Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis. Cerebrovascular Diseases. 2023;52(3):255-265. doi:10.1159/000526896
BibTeX
@article{Koyanagi2023,
author = {Koyanagi, Masaomi and Hatano, Taketo and Uchida, Kazutaka and Ogura, Takenori and Yamagami, Hiroshi and Shibata, Masunari and Enomoto, Yukiko and Fukawa, Norihito and Matsumoto, Yasushi and Sakai, Nobuyuki and Takeuchi, Masataka and Nonaka, Tadashi and Shimizu, Fuminori and Ezura, Masayuki and Ota, Takahiro and Ohta, Hajime and Morimoto, Masafumi and Morimoto, Takeshi and Yoshimura, Shinichi and ALVO investigators, ALVO investigators},
title = {Safety of Apixaban Monotherapy for Non-Valvular Atrial Fibrillation-Related Acute Stroke with Intra-/Extracranial Artery Stenosis},
journal = {Cerebrovascular Diseases},
year = {2023},
volume = {52},
number = {3},
pages = {255--265},
doi = {10.1159/000526896}
}
EUVIMED